Ladiratuzumab Biosimilar (LIV-1 / SLC39A6 Reference Antibody)
Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC) . Ladiratuzumab can be used for research of breast cancer.
Product Specifications
Target
Ladiratuzumab Biosimilar (Anti-LIV-1 / SLC39A6 Reference Antibody)
Clonality
Monoclonal
Conjugation
Unconjugated
Purity
>98%
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog